FTC Targets Disclosures, “Up To” And “Doctor Recommended” Claims
This article was originally published in The Tan Sheet
Executive Summary
“A lot of research casts doubt on the effectiveness of disclosures,” says FTC official Richard Cleland. FTC will also zero in on “up-to,” “doctor recommended,” business-to-business, immunity and weight loss claims.
You may also be interested in...
No Clean Bill Of Health For Rite Aid's '#1 Doctor Recommended' Claims
Rite Aid discontinues “#1 doctor recommended” and similar claims promoting OTC drug, dietary supplement and other health and wellness brands when National Advertising Division reminds firm that retailers cannot rely on suppliers' assertion of accuracy about claims but must have their own substantiation.
In Brief: laxatives warning, FTC settlement, ChromaDex inks 5LINX deal
Sodium phosphate laxatives linked to SAERs; FTC scrutinizes personalized supplement claims; NAD refers Xlear LLC to FTC; ChromaDex inks marketing deal with 5LINX; CVS launches vitamin sales, info hub on its website; Star Scientific shareholder suit proceeds.
FTC Settles Big With Sensa, Other Weight-Loss Marketers
FTC settles with Sensa products and three other weight-loss product marketers, and launches its “gut check” voluntary media partnership program to prevent bogus claims. A firm cited in FTC’s 2011 investigation of human chorionic gonadotropin product ads also reached a settlement with the agency.